Early diagnosis is key to improving outcomes in patients with multiple sclerosis (MS), as treatment initiation early in the disease course can help mitigate symptoms and slow disease progression. Recent advances in the pathophysiology of MS have led to new disease-modifying therapies (DMTs) that have the potential to halt or significantly slow disease progression and provide the first-available treatment for patients with primary progressive MS.
At the conclusion of this activity, participants will be able to:summarize the latest clinical data of available imaging tools that assess prostate cancer recurrence and anticipate practical factors to consider when implementing new imaging techniques in the prostate cancer clinic
During this expert faculty will update the cystic fibrosis care team, specifically pulmonologists and endocrinologists, on the evolving landscape of screening, diagnosis, and treatment options for the management of patients with CF who have diabetes.
Conventional treatment of hyperkalemia is restricted by adverse events, as well as a dearth of evidence supporting clinical use. Recent research has led to the development of two novel potassium binders with good safety profiles that allow patients to maintain or increase the use of RAASIs for cardio- and reno-protection.